$100.01▼ 0.78 (0.77%)
Real-time prices · US MarketsEarnings growing 1188% year-over-year on 32% revenue growth.
Quality
9.3
Health
8.2
Growth
10
Valuation
8.4
Sentiment
7.8
Analyst Target
$156.00
▲ +56.0% from current
Price Chart
Latest News
- TransMedics Group Agrees to Invest in PAD Aviation for European Transplant Logistics Network
- TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
- TransMedics Unveils CHOPS As Trials Progress And Valuation Screens Undervalued
Fundamentals
Trailing P/E
20.5×
price-to-earnings
Forward P/E
27.2×
next 12 months est.
Market Cap
$3.5B
market capitalization
Div Yield
—
dividend yield
Profit Margin
31.4%
net profit margin
Gross Margin
59.9%
revenue minus COGS
ROE
54.2%
return on equity
Beta
2.08
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$90 — $156
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is TMDX a good stock to buy right now?
TransMedics Group, Inc.'s Q·Score is 8.8/10 (Very Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Earnings growing 1188% year-over-year on 32% revenue growth. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for TMDX?
The consensus price target for TMDX is $156.00, based on ratings from 10 Wall Street analysts. This is 56.0% above the current price of $100.01. Price targets are forward-looking estimates and not guarantees of future performance.
Is TMDX overvalued or undervalued?
TransMedics Group, Inc. (TMDX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 27.2×. The consensus analyst price target of $156.00 is 56% above the current price.
When does TransMedics Group, Inc. report its next earnings?
TransMedics Group, Inc. is scheduled to report earnings in 2 days, on May 5, 2026.
What is TransMedics Group, Inc.'s profit margin?
TransMedics Group, Inc. has a net profit margin of 31.4%, which is considered high and reflects strong pricing power. Its gross margin stands at 59.9%, indicating a high-margin business model.
Is TransMedics Group, Inc.'s revenue growing?
TransMedics Group, Inc. is reporting strong year-over-year growth of 32.2%. Earnings are also growing at 1188.1%, indicating improving profitability.
How much debt does TransMedics Group, Inc. have?
TransMedics Group, Inc. has a debt-to-equity ratio of 1.10×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 7.14×, indicating comfortable short-term liquidity.